FDA orphan drug designation: treatment of myasthenia gravis (MG)
All entries for: COUR Pharmaceuticals Development Company Inc.
September 12, 2025
COUR Pharmaceuticals Development Company Inc.
Orphan Drug Designation
Disease Area: Rare Diseases
